Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells

Randall W. Alfano, Stephen H. Leppla, Shihui Liu, Thomas H. Bugge, Meenhard Herlyn, Keiran S. Smalley, Jennifer L. Bromberg-White, Nicholas S. Duesbery, Arthur E. Frankel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is composed of two proteins, protective antigen and lethal factor. Uptake of the toxin into cells is dependent on proteolytic activation of protective antigen by the ubiquitously expressed furin or furin-like proteases. To circumvent nonspecific LeTx activation, a substrate preferably cleaved by gelatinases was substituted for the furin LeTx activation site. Here, we have shown that the toxicity of this matrix metalloproteinase (MMP)-activated LeTx is dependent on host cell surface MMP-2 and MMP-9 activity as well as the presence of the activating V600E B-RAF mutation, making this toxin dual specific. This additional layer of tumor cell specificity would potentially decrease systemic toxicity from the reduction of nonspecific toxin activation while retaining antitumor efficacy in patients with V600E B-RAF melanomas. Moreover, our results indicate that cell surface-associated gelatinase expression can be used to predict sensitivity among V600E B-RAF melanomas. This finding will aid in the better selection of patients that will potentially respond to MMP-activated LeTx therapy.

Original languageEnglish (US)
Pages (from-to)1218-1226
Number of pages9
JournalMolecular Cancer Therapeutics
Volume7
Issue number5
DOIs
StatePublished - 2008

Fingerprint

Matrix Metalloproteinase 9
Matrix Metalloproteinases
Melanoma
Furin
Gelatinases
Antigens
Mutation
Matrix Metalloproteinase 2
Mitogen-Activated Protein Kinases
Patient Selection
Peptide Hydrolases
anthrax toxin
Apoptosis
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. / Alfano, Randall W.; Leppla, Stephen H.; Liu, Shihui; Bugge, Thomas H.; Herlyn, Meenhard; Smalley, Keiran S.; Bromberg-White, Jennifer L.; Duesbery, Nicholas S.; Frankel, Arthur E.

In: Molecular Cancer Therapeutics, Vol. 7, No. 5, 2008, p. 1218-1226.

Research output: Contribution to journalArticle

Alfano, Randall W. ; Leppla, Stephen H. ; Liu, Shihui ; Bugge, Thomas H. ; Herlyn, Meenhard ; Smalley, Keiran S. ; Bromberg-White, Jennifer L. ; Duesbery, Nicholas S. ; Frankel, Arthur E. / Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 5. pp. 1218-1226.
@article{e96e2a95b3284f88ab2e52dd34dad02a,
title = "Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells",
abstract = "Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is composed of two proteins, protective antigen and lethal factor. Uptake of the toxin into cells is dependent on proteolytic activation of protective antigen by the ubiquitously expressed furin or furin-like proteases. To circumvent nonspecific LeTx activation, a substrate preferably cleaved by gelatinases was substituted for the furin LeTx activation site. Here, we have shown that the toxicity of this matrix metalloproteinase (MMP)-activated LeTx is dependent on host cell surface MMP-2 and MMP-9 activity as well as the presence of the activating V600E B-RAF mutation, making this toxin dual specific. This additional layer of tumor cell specificity would potentially decrease systemic toxicity from the reduction of nonspecific toxin activation while retaining antitumor efficacy in patients with V600E B-RAF melanomas. Moreover, our results indicate that cell surface-associated gelatinase expression can be used to predict sensitivity among V600E B-RAF melanomas. This finding will aid in the better selection of patients that will potentially respond to MMP-activated LeTx therapy.",
author = "Alfano, {Randall W.} and Leppla, {Stephen H.} and Shihui Liu and Bugge, {Thomas H.} and Meenhard Herlyn and Smalley, {Keiran S.} and Bromberg-White, {Jennifer L.} and Duesbery, {Nicholas S.} and Frankel, {Arthur E.}",
year = "2008",
doi = "10.1158/1535-7163.MCT-08-0024",
language = "English (US)",
volume = "7",
pages = "1218--1226",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells

AU - Alfano, Randall W.

AU - Leppla, Stephen H.

AU - Liu, Shihui

AU - Bugge, Thomas H.

AU - Herlyn, Meenhard

AU - Smalley, Keiran S.

AU - Bromberg-White, Jennifer L.

AU - Duesbery, Nicholas S.

AU - Frankel, Arthur E.

PY - 2008

Y1 - 2008

N2 - Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is composed of two proteins, protective antigen and lethal factor. Uptake of the toxin into cells is dependent on proteolytic activation of protective antigen by the ubiquitously expressed furin or furin-like proteases. To circumvent nonspecific LeTx activation, a substrate preferably cleaved by gelatinases was substituted for the furin LeTx activation site. Here, we have shown that the toxicity of this matrix metalloproteinase (MMP)-activated LeTx is dependent on host cell surface MMP-2 and MMP-9 activity as well as the presence of the activating V600E B-RAF mutation, making this toxin dual specific. This additional layer of tumor cell specificity would potentially decrease systemic toxicity from the reduction of nonspecific toxin activation while retaining antitumor efficacy in patients with V600E B-RAF melanomas. Moreover, our results indicate that cell surface-associated gelatinase expression can be used to predict sensitivity among V600E B-RAF melanomas. This finding will aid in the better selection of patients that will potentially respond to MMP-activated LeTx therapy.

AB - Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is composed of two proteins, protective antigen and lethal factor. Uptake of the toxin into cells is dependent on proteolytic activation of protective antigen by the ubiquitously expressed furin or furin-like proteases. To circumvent nonspecific LeTx activation, a substrate preferably cleaved by gelatinases was substituted for the furin LeTx activation site. Here, we have shown that the toxicity of this matrix metalloproteinase (MMP)-activated LeTx is dependent on host cell surface MMP-2 and MMP-9 activity as well as the presence of the activating V600E B-RAF mutation, making this toxin dual specific. This additional layer of tumor cell specificity would potentially decrease systemic toxicity from the reduction of nonspecific toxin activation while retaining antitumor efficacy in patients with V600E B-RAF melanomas. Moreover, our results indicate that cell surface-associated gelatinase expression can be used to predict sensitivity among V600E B-RAF melanomas. This finding will aid in the better selection of patients that will potentially respond to MMP-activated LeTx therapy.

UR - http://www.scopus.com/inward/record.url?scp=49849093232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849093232&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0024

DO - 10.1158/1535-7163.MCT-08-0024

M3 - Article

C2 - 18483309

AN - SCOPUS:49849093232

VL - 7

SP - 1218

EP - 1226

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -